BioRxiv Fernandez-Castaneda A, .
Jan 10th, 2022 - Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI).
Eurosurveillance Brandal LT, .
Dec 15th, 2021 - On 30 November 2021 the Norwegian Institute of Public Health (NIPH) was notified by a local laboratory in Oslo of a coronavirus disease (COVID-19) case with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.1.529 BA.1) infection . The laboratory provided...
NIH Director's Blog; Collins FS.
Dec 14th, 2021 - There’s been great concern about the new Omicron variant of SARS-CoV-2, the coronavirus that causes COVID-19. A major reason is Omicron has accumulated over 50 mutations, including about 30 in the spike protein, the part of the coronavirus that mRNA vaccines teach our immune systems to attack. All of these genetic changes raise the possibility that Omicron could cause breakthrough infections in...
Science Cohn BA, .
Nov 4th, 2021 - The messenger RNA vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) and the viral vector vaccine JNJ-78436735 (Janssen) have effectively prevented clinically significant disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since their rollout in the U.S. in late 2020 (1, 2).
Medrxiv Atmar RL, .
Oct 13th, 2021 - Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.
Jan 23rd, 2022 - A new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.1.529, was identified in Botswana and South Africa in early November 2021 and was designated as variant of concern (VOC) Omicron by the World Health Organization on November 26, 2021 (1). As of December 1, 2021, ≈220 sequences were available on GISAID (https://www.gisaid.org), and this variant has been detected i...
Proceedings of the National Academy of Sciences of the Un... Despres HW, Mills MG et. al.
Jan 22nd, 2022 - Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants pose a challenge to controlling the COVID-19 pandemic. Previous studies indicate that clinical samples collected from individuals infected with the Delta variant may contain higher levels of RNA than previous variants, but the relationship between levels of viral RNA and infectious virus for individual variants is unkno...
Emerging Microbes & Infections; Zhang X, Chu H et. al.
Jan 22nd, 2022 - Host circular RNAs (circRNAs) play critical roles in the pathogenesis of viral infections. However, how viruses modulate the biogenesis of host proviral circRNAs to facilitate their replication remains unclear. We have recently shown that Middle East respiratory syndrome coronavirus (MERS-CoV) infection increases co-expression of circRNAs and their cognate messenger RNAs (mRNAs), possibly by hi...
Journal of Cardiac Surgery; Zalle I, Barthelemy Y et. al.
Jan 22nd, 2022 - The coronavirus disease 2019 (COVID-19) causes a small proportion of patients to be admitted to intensive care units, where they sometimes require extracorporeal membrane oxygenation (ECMO). The literature on pregnant women with COVID-19 who require ECMO is sparse. We describe here the earliest-fetal-age pregnant patient with COVID-19 who underwent ECMO yet reported, who kept her child while un...
https://doi.org/10.1007/s11882-022-01026-1 10.15585/mmwr.mm6950a4 10.1177/1357633X16652288 10.1089/tmj.2013.0256 10.1089/tmj.2017.0265 10.1016/j.mayocpiqo.2021.06.006 10.1097/ACM.0000000000003711 10.1007/s11606-020-05878-z 10.1177/1357633X16644095 10.1016/j.jaad.2017.09.017 10.1001/jamainternmed.2020.5928 10.15585/mmwr.mm7007a3
Current Allergy and Asthma Reports; Greiwe J
Jan 22nd, 2022 - Prior to the SARS-CoV-2 novel coronavirus (COVID-19) pandemic, access and utilization of telemedicine in the USA was negligeable, with very little interest from both the public and healthcare sectors. Since that time, telemedicine technology and services have undergone explosive growth and investment and are poised to change the way healthcare is delivered now and in the future. But has telemed...
https://doi.org/10.1038/s41467-021-27893-2 10.1126/science.abf2946 10.1016/j.cell.2020.02.052 10.1126/science.abb2762 10.1126/science.abc6952 10.1126/science.abd0831 10.1002/jmv.26241 10.1126/science.abc2241 10.1126/science.abc5902 10.1126/science.abc7520 10.1126/science.abd0827 10.1038/s41586-020-2381-y 10.1038/s41586-020-2380-z 10.1681/ASN.2020101537 10.1056/NEJMoa2035002 10.1056/NEJMoa2033130 10.1038/s41586-021-03777-9 10.1056/NEJMoa2031893 10.1016/j.tcb.2020.09.009 10.1016/j.jinf.2020.06.067
Nature Communications; El-Shennawy L, Hoffmann AD et. al.
Jan 22nd, 2022 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of concern. It remains urgent to identify novel approaches against broad strains of SARS-CoV-2, which infect host cells via the entry receptor angiotensin-converting enzyme 2 (ACE2). Herein, we report an increase in circulating extrac...
International Journal of Molecular Medicine; Zurlo M, Nicoli F et. al.
Jan 22nd, 2022 - The pandemic caused by the severe acute respiratory syndrome coronavirus (SARS‑CoV‑2), responsible for coronavirus disease 2019 (COVID‑19) has posed a major challenge for global health. In order to successfully combat SARS‑CoV‑2, the development of effective COVID‑19 vaccines is crucial. In this context, recent studies have highlighted a high COVID‑19 mortality rate in patients affected by β‑th...
Jan 22nd, 2022 - As of August 2021, South Korea is in the middle of a fourth community epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, which is now predominated by the B.1.617.2 lineage (Delta variant) (1,2). The epidemic size largely depends on such epidemiologic characteristics as serial interval distribution and transmissibility (3,4). For the Delta variant of SARS-CoV-...
Jan 22nd, 2022 - Serosurveys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Greater Mekong Subregion (GMS) of Cambodia have been limited to those screening healthcare workers in 2 urban hospital-based settings (1,2). These antibody-based studies are necessary to determine at-risk populations and direct disease containment measures; however, before informing public health decisions, sero...
Jan 22nd, 2022 - Through November 9, 2021, Bangladesh had reported >1.57 million COVID-19 cases and 27,904 deaths (1), with incidence and mortality rates substantially lower than in many other countries. Without performing population-based seroprevalence estimates, it is difficult to know whether differences in rates of illness and death result from undercounts because of limited surveillance and healthcare see...
Jan 22nd, 2022 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 lineage, also known as Delta variant of concern (VOC), first sequenced in India in December 2020, was identified in Portugal in late April and quickly became dominant, reaching 90% of all sequenced cases in late June 2021 (epidemiologic week 26), just 2 months after it was first identified (1). Available evidence suggest...
Jan 21st, 2022 - The purpose of this study is to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
https://doi.org/10.1186/s13023-021-02147-y 10.1002/humu.23860 10.1016/j.pediatrneurol.2017.01.034 10.2147/TCRM.S241048 10.1056/NEJMoa1712649 10.1177/2326409818788382 10.1136/bmj.m4436 10.1186/s13023-020-01619-x 10.3390/children8090781 10.1016/j.ymgme.2020.09.004 10.1186/s13023-021-02007-9 10.1515/jpem-2021-0067 10.1016/j.ymgme.2020.04.002 10.1186/s13023-021-01734-3 10.1046/j.1365-2648.1994.20040716.x
Orphanet Journal of Rare Diseases; Mortensen A, Raebel EM et. al.
Jan 21st, 2022 - Cerliponase alfa, an enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2), is currently available in England through a managed access agreement (MAA). It is administered every 2 weeks via an intracerebroventricular device. Here we report qualitative research with families of children with CLN2 disease and healthcare professionals (HCPs) who run the MAA, to understand how ...
Nature Chemical Biology; Zhang L, Dutta S et. al.
Jan 21st, 2022 - Vaccine hesitancy and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) escaping vaccine-induced immune responses highlight the urgency for new COVID-19 therapeutics. Engineered angiotensin-converting enzyme 2 (ACE2) proteins with augmented binding affinities for SARS-CoV-2 spike (S) protein may prove to be especially efficacious against multip...
World Journal of Gastroenterology; Roy K, Agarwal S et. al.
Jan 21st, 2022 - The disease coronavirus disease 2019 (COVID-19) is a severe respiratory illness that has emerged as a devastating health problem worldwide. The disease outcome is heterogeneous, and severity is likely dependent on the immunity of infected individuals and comorbidities. Although symptoms of the disease are primarily associated with respiratory problems, additional infection or failure of other v...